# 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

> **NCT03993171** · PHASE2 · COMPLETED · sponsor: **Clene Nanomedicine** · enrollment: 33 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** gold nanocrystals

## Key facts

- **NCT ID:** NCT03993171
- **Lead sponsor:** Clene Nanomedicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-19
- **Primary completion:** 2025-05-27
- **Final completion:** 2025-07-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993171, "31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03993171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*